PlainRecalls
ModerateClass IITerminated

FDA Drug recall · Reported April 24, 2019

Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.

Presence of Particulate Matter.

Recall #
D-1125-2019
Affected scope
75968 vials
Initiated
March 22, 2019
Verify with FDA Drug →
View my saved recalls

InvaGen Pharmaceuticals, Inc. recalled Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use o… - a moderate-severity action.

Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use o… was recalled by InvaGen Pharmaceuticals, Inc. in April 24, 2019. Reason: Presence of Particulate Matter.. Check the official notice for the remedy. Verify recall #D-1125-2019 with the FDA Drug before acting.

The recall

InvaGen Pharmaceuticals, Inc. issued this moderate-severity FDA Drug recall-Presence of Particulate Matter..

Moderate
severity level
Class II
classification
April 24, 2019
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-1125-2019 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-1125-2019) was formally reported on April 24, 2019, with the manufacturer initiating the action on March 22, 2019. It is classified under Moderate severity (Class II), with a current status of Terminated. InvaGen Pharmaceuticals, Inc. is listed as the recalling firm, operating out of Central Islip, NY. Federal records list the affected scope as 75968 vials.

The documented reason for this recall is: Presence of Particulate Matter. Distribution data in the federal record shows the product reached: Nationwide in the U.S.A.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,287 drugs & medications recalls on record

-50005001,0001,5002,000 2006201220152018202120242026 263
Severity2487872426High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Severity

Moderate

Affected scope

75968 vials

Related Recalls

6

5 from same agency

Product description

Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.

Reason for recall

Presence of Particulate Matter.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Moderate (Class II)
Status Terminated
Recall number D-1125-2019
Date reported April 24, 2019
Date initiated March 22, 2019
Recalling firm InvaGen Pharmaceuticals, Inc.
Firm location Central Islip, NY
Affected scope 75968 vials
Distribution Nationwide in the U.S.A.

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-1125-2019) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.. Recalled by InvaGen Pharmaceuticals, Inc.. Units affected: 75968 vials.
Why was this product recalled?
Presence of Particulate Matter.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 24, 2019. Severity: Moderate. Recall number: D-1125-2019.
Where was the recalled product distributed?
Distribution: Nationwide in the U.S.A..
How do I check if my product is affected by a recall?
Check the product description and recall number (D-1125-2019) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →

Browse all Drugs & Medications recalls →

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported April 24, 2019. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.